Acetyl coenzyme A kinetic studies on N-acetylation of environmental carcinogens by human N-acetyltransferase 1 and its NAT1*14B variant

Mariam R. Habil, Mark A. Doll and David W. Hein*

Department of Pharmacology & Toxicology, University of Louisville School of Medicine, Louisville, KY, United States

N-acetyltransferase 1 (NAT1) is a xenobiotic metabolizing enzyme that uses acetyl coenzyme A (AcCoA) as a cofactor for N-acetylation of many carcinogens including aromatic amines and alkylanilines. NAT1 is characterized by single nucleotide polymorphisms (SNPs) that may modulate affinity towards AcCoA. In the current study, we used Chinese hamster ovary (CHO) cells stably transfected with human NAT1*4 (reference allele) or NAT1*14B (variant allele) to measure AcCoA kinetic parameters for N-acetylation of p-aminobenzoic acid (PABA), 4-aminobiphenyl (4-ABP), β-naphthylamine (BNA), benzidine and 3,4-dimethylaniline (3,4-DMA). Our results showed higher N-acetylation rates for each substrate catalyzed by NAT1*4 compared to NAT1*14B. NAT1*4 exhibited higher affinity to AcCoA when catalyzing the N-acetylation of BNA and benzidine compared to NAT1*14B. The results of the current study provide further insights into differences in carcinogen metabolism among individuals possessing the NAT1*14B haplotype.

KEYWORDS
arylamine N-acetyltransferase 1, acetyl coenzyme A, 4-aminobiphenyl, β-naphthylamine, benzidine, 3, 4-dimethylaniline

Introduction

Arylamine N-acetyltransferases (NATs) are xenobiotic metabolizing enzymes which play important roles in the metabolism and detoxification of many drugs and carcinogens (Walraven et al., 2008b). Two NATs (N-acetyltransferase 1; NAT1 and N-acetyltransferase 2; NAT2) have been characterized in humans with similar structure (Sim et al., 2008). However, they exhibit different physiological roles and substrate affinities (Sim et al., 2003; Doll et al., 2010). NAT1 shows substrate specificity for p-aminobenzoic acid (PABA), while NAT2 shows substrate specificity for sulfamethazine (Hein, 2006).

NAT1 is a polymorphic enzyme due to single nucleotide polymorphisms or SNPs associated with decreased enzyme activity and changes in protein stability.
subject to fluctuation upon variations in its synthesis and use. Moreover, it can be affected by the fed and the metabolic states of cells (Pietrocola et al., 2015; Shi and Tu, 2015). NAT1 catalyzes the hydrolysis of AcCoA in a folate-dependent manner (Laurieri et al., 2014; Stepp et al., 2015). Also, MDA-MB-231 and MCF-7 NAT1 knockout human breast cancer cell lines exhibit increased AcCoA levels relative to their respective parental cell lines (Stepp et al., 2019). Previous studies showed that AcCoA affects protein acetylation and acetylation of NAT1 enhances its activity as it prevents its proteasomal degradation (Butcher et al., 2004; Bradshaw, 2021). However, the kinetics of AcCoA and its effect on N-acetylation of environmental carcinogens need to be investigated. The aim of this study is to compare AcCoA kinetics between human NAT1*4 and the NAT1*14B variant expressed in mammalian cell cultures.

**Materials and methods**

**Chemicals.** Acetyl-CoA, para-aminobenzoic acid (PABA), N-acetyl PABA, 4-aminobiphenyl (4-ABP), N-acetyl ABP, β-naphthylamine (BNA), N-acetyl BNA, benzidine and 3,4-dimethylaniline (3,4-DMA) were purchased from Sigma Aldrich. N-acetyl-benzidine or 3'-4-(amino-[1,1'-biphenyl]-4-yl) acetamide was purchased from Alinda Chemical (Moscow, Russia). N-acetyl 3,4 DMA or N-(3,4-dimethylphenyl) acetamide was purchased from BIONET/Key Organics Ltd. (Cornwall, United Kingdom).

**Chinese Hamster Ovary (CHO) Cells.** UV5-CHO cells that express human CYP1A2 and NAT1*4 or NAT1*14B were constructed and characterized as previously described (Millner et al., 2012a; Millner et al., 2012b). UV5/CHO cells, a nuclease excision repair-deficient derivative of AA8 that are hypersensitive to bulky DNA lesions, were obtained from the American Type Culture Collection. Cells were grown in alpha-modified minimal essential medium (Cambrex) without L-glutamine, ribosides, and deoxyribosides supplemented with 10% fetal bovine serum (Hyclone), 100 units/ml penicillin, 100 μg/ml streptomycin (Cambrex), and 2 mM L-glutamine (Cambrex) at 37°C in 5% CO₂. The cells used in this study were previously stably transfected with a single FRT integration site. The FRT site allowed stable transfections to use the Fp-In System (Invitrogen). The FRT site allows recombination to occur immediately downstream of the hygromycin resistance gene, allowing for hygromycin selectivity only after Fp-recombinase-mediated integration. The UV5/FRT cells were further modified by stable integration of human CYP1A2 and NADPH-cytochrome P450 reductase gene. These cells were expanded, and intact genicin-resistant cells were assayed for CYP1A2 activity by measuring 7-ethoxyresorufin O-deethylase (EROD) activity as previously described (Bendaly et al., 2007). UV5/1A2 cells were stably transfected with pcDNA5/FRT containing NATb/ NAT1*4 and NATb/NAT1*14B constructs using Effectene transfection reagent (QIAGEN, Valencia, CA) following the manufacturer’s recommendations. Because the pcDNA5/FRT vector contains a hygromycin resistance...
cassette, 120 g/ml hygromycin (Invitrogen) was added to media to select for cells containing the pcDNA5/FRT plasmid. The amount of NAT1 produced in UV5/1A2 cells stably transfected with NAT1*4 or NAT1*14B was determined by Western blot (Millner et al., 2012b). The NAT1*4 and NAT2*14B-transfected cells were characterized for N-acetylation of PABA, a NAT1-selective substrate as described below. NAT1 haplotypes were determined by allele specific polymerase chain reaction as previously described (Doll and Hein, 2002). Quantitative RT-PCR (RT-qPCR) assays were used to assess the relative amount of CYP1A2 mRNA in cells in CHO cells and CYP1A2 protein expression was measured using in cell western protocol as previously described (Habil et al., 2022).

Cell lysate preparation. CHO cells were lysed in 20 mM sodium phosphate buffer (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, 100 μM phenylmethanesulfonyl fluoride, Pierce protease inhibitor minitablets (Thermo Scientific) plus 0.2% triton-x-100 (Sigma). Lysates were then placed on a rotator at 4°C for 10 min. Then lysates were centrifuged at 15,000 g at 4°C for 20 min and the supernatant was removed, aliquoted and assayed for enzymatic activity as described below.

N-acetyltransferase assays. In vitro N-acetyltransferase assays were done by using cell lysates of UV5-CHO cells stably expressing CYP1A2 and either NAT1*4 or NAT1*14B. AcCoA kinetic constants were determined from assays conducted in the presence of 250 μM PABA, 4-ABP, BNA, benzidine or 3,4-DMA with varying concentrations (31.3–1,000 μM) of AcCoA. The reaction was terminated by the addition of 1/10 volume of 1 M acetic acid. Reaction tubes were centrifuged at 15,000 × g for 10 min to precipitate protein. PABA, 4-ABP, BNA, benzidine, 3,4-DMA and their N-acetylated products were separated and identified by high performance liquid chromatography (HPLC) following injection (40 μL) onto a 125 × 4 mm LiChrospher 100 RP-100 5 μm C18 HPLC column.

The amounts of PABA and acetyl-PABA produced was determined following separation and quantitation by HPLC subjected to a gradient of 96% 20 mM sodium perchlorate pH 2.5/4% acetonitrile to 88% 20 mM sodium perchlorate pH 2.5/12% acetonitrile over 7 min, then to 85% 20 mM sodium perchlorate pH 2.5/15% acetonitrile over 4 min.
Retention times for PABA and acetyl-PABA were 2.5 and 8.8 min, respectively. The UV detector was set at 280 nm.

The amounts of acetyl-ABP and acetyl-BNA produced were determined following separation and quantitation by HPLC subjected to a gradient of 85% 20 mM sodium perchlorate pH 2.5/15% acetonitrile for 15 min to 65% 20 mM sodium perchlorate pH 2.5/35% acetonitrile over 2.5 min, then to 85% 20 mM sodium perchlorate pH 2.5/15% acetonitrile over 2.5 min. Retention times for 4-ABP and acetyl-ABP were 9.5 and 12.5 respectively and for BNA and acetyl-BNA, retention times were 3.97 and 10.1 min, respectively. The UV detector was set at 260 nm.

For benzidine and 3,4-DMA, the amounts of benzidine and 3,4-DMA and their N-acetylated products produced were determined following separation and quantitation by HPLC subjected to a gradient of 100% 20 mM sodium perchlorate pH 2.5/0% acetonitrile for 5 min to 0% 20 mM sodium perchlorate pH 2.5/100% acetonitrile over 10 min, then to 100% 20 mM sodium perchlorate pH 2.5/0% acetonitrile over 5 min. Retention times for benzidine and acetyl-benzidine were 6.9 and 8.5 min respectively and for 3,4-DMA and acetyl-3,4-DMA were 8.08 and 10.1 respectively. The UV detector was set at 320 nm for benzidine and 250 nm for 3,4-DMA.
For all samples, protein concentrations of cell lysates were determined using the Bio-Rad protein assay kit (Bio-Rad, Richmond, CA) and activity was calculated in nmoles of acetylated product/ml/min/mg protein.

**Statistical analysis**

Kinetic parameters apparent AcCoA $K_m$ and $V_{max}$ were calculated using the Michaelis-Menten equation. Differences in apparent AcCoA $K_m$ and $V_{max}$ values were tested for significance by unpaired student $t$-test. To compare apparent $K_m$ and $V_{max}$ values for all substrates with the same allele, we used one-way analysis of variance (ANOVA) followed by Tukey test or two-way analysis of variance (ANOVA) followed by Bonferroni test (Graph Pad Prism 9).

**Results**

In this study, we used CHO mammalian cells which express human CYP1A2 and either human NAT1*4 or NAT1*14B. The NAT1*14B variant is characterized by single nucleotide polymorphism (SNP) at G560A (R187Q) leading to change in the active site of the enzyme that affect affinity towards PABA (Zhu and Hein, 2008).
First, we validated CHO cells and our results showed that CYP1A2 mRNA and protein levels were elevated in CYP1A2-transfected compared to non-transfected (control) CHO cells and did not differ significantly between the CHO cells transfected with CYP1A2 and NAT1*4 or NAT1*14B (Figures 1A,B). CHO cells containing NAT1*4 or NAT1*14B were confirmed by allele-specific amplification as previously described (Doll and Hein, 2002). N-acetylation of PABA was measured to confirm the NAT1 alleles, with higher N-acetylation activity in CHO cells expressing NAT1*4 (p < 0.0001) than in CHO cells expressing NAT1*14B (Figure 2).

Our results report that in vitro N-acetylation rates for all substrates were AcCoA concentration dependent. First, we used PABA which is the prototypic substrate for NAT1. NAT1*4 showed higher AcCoA apparent Vmax compared to NAT1*14B (p < 0.001) (Figure 3C). AcCoA apparent Km did not differ significantly between NAT1*4 and NAT1*14B (Figure 3B). For 4-ABP, NAT1*4 had higher apparent AcCoA Vmax (Figure 4C) compared to NAT1*14B (p < 0.001). However, no significant difference was observed regarding their affinity towards AcCoA (Figure 4B). In the presence of BNA, NAT1*4 had higher affinity towards AcCoA compared to NAT1*14B (Figure 5B) reflected by the lower apparent Km (1.5-fold, p < 0.001). AcCoA Vmax was significantly higher in NAT1*4 compared to NAT1*14B (p < 0.001) (Figure 5C). AcCoA kinetic constants in the presence of benzidine showed similar pattern with apparent Vmax higher in NAT1*4 compared to NAT1*14B (p < 0.001) (Figure 6C) and higher affinity towards AcCoA (apparent Km value in NAT1*4 was 2.6-fold lower than NAT1*14B (p < 0.05) (Figure 6B). AcCoA apparent Vmax in the presence of 3,4-DMA in NAT1*4 was higher in NAT1*4 compared to NAT1*14B (Figure 7C) (p < 0.001). However, AcCoA apparent Km values did not significantly differ (Figure 7B).
Comparing AcCoA apparent Km values across substrates revealed that both NAT1*4 (p < 0.001) and NAT1*14B (p < 0.0001) have higher affinity to bind to AcCoA in presence of benzidine compared to the other carcinogens (Figure 8A). In contrast, the AcCoA apparent Vmax values across substrates were higher for NAT1*4 than NAT1*14B (Figure 8B).

Discussion

The G560A (R187Q) SNP associated with NAT1*14B has been reported to modify apparent Km towards PABA and ABP, albeit in opposite directions for these two aromatic amines (Zhu and Hein, 2008). A previous study showed that the apparent Km of NAT1*14B was higher for PABA compared to NAT1*4 (Zhu and Hein, 2008), whereas the apparent Km of NAT1*14B was lower for 4-ABP and N-OH-ABP compared to NAT1*4 (Millner et al., 2012b). Also, Zhu and Hein compared AcCoA Km and there was no significant difference in AcCoA Km between NAT1*4 and NAT1*14B in presence of PABA (Zhu and Hein, 2008). Our current study confirmed similar results for AcCoA Km values using PABA as a substrate. Nevertheless, AcCoA kinetic constants in the presence of carcinogens showed that NAT1*4 exhibited higher affinity towards AcCoA compared to NAT1*14B using BNA and benzidine as substrates (p < 0.001 and p < 0.05 respectively).

NAT1*14B showed lower Vmax than NAT1*4 for PABA, 4-ABP, and N-OH-ABP consistent with decreased ability of NAT1*14B to metabolize these substrates compared to NAT1*4 (Millner et al., 2012b). In the current study, we found similar results for N-acetylation of all carcinogens. Apparent Vmax for all substrates were higher in NAT1*4 compared to NAT1*14B. This is consistent with the effects of the G560A (R187Q) SNP in COS-1 cells (Doll and Hein, 2022).

Previous studies have shown that the intracellular acetyl CoA level can be affected by many factors including the fasting and the fed states and this in turn can affect acetylation of many proteins including enzymes (Xiong and Guan, 2012; Carrer et al., 2017). Our study showed that NAT1*4 has higher affinity for AcCoA compared to NAT1*14B. This may allow NAT1*4 to be in a more acetylated state consistent with higher N-acetylation activity.

In addition, comparison of AcCoA Km values within the same allele across different substrates revealed that NAT1*4 and NAT1*14B exhibited higher affinity to AcCoA in presence of benzidine compared to other substrates as reflected by the lower apparent AcCoA Km. This suggests the affinity towards AcCoA is dependent on the carcinogen substrate and is higher towards benzidine than other substrates. The N-acetylation of benzidine likely leads to its activation (Degen et al., 2004; Carreon et al., 2006).

A summary of the results of this study is illustrated in Figure 9. In vitro N-acetylation rate towards all substrates was higher in CHO cells expressing NAT1*4 than NAT1*14B (as shown in Figures 3A, 4A, 5A, 6A, 7A). Strengths of this study included that we have used a model stably transfected with human CYP1A2 and NAT1 alleles and used it to study human carcinogen metabolism. Also, we have included NAT1*14B allele which is an important variant associated with lung and urinary bladder cancer. In addition, we have developed HPLC methods to measure the N-acetylation of aromatic amines and alkylanilines that can be optimized to be used in human serum or urine samples. Furthermore, our study investigated the effect of NAT1 allelic variation on the affinity towards AcCoA which is an important regulatory cofactor for many cellular processes. On the other hand, some limitations were that we have compared only two NAT1 alleles for NAT1 enzyme. Also, we did not use human cell lines. Further studies should include other NAT1 allelic variants and use of human cell lines.
Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

MH: Formal analysis, investigation, writing—review and editing. This work constitutes partial fulfillment by MH for the PhD in pharmacology and toxicology at the University of Louisville. MD: Formal analysis, investigation, writing—review and editing. DH: Conceptualization, methodology, validation, formal analysis, resources, writing—review and editing, visualization, supervision.

Funding

Portions of this work were funded by NIH grants P20-GM113226; P42-ES023716; and P30-ES030283.

References

Barnes, J. L., Zubair, M., John, K., Poirier, M. C., and Martin, F. L. (2018). Carcinogens and DNA damage. Biochem. Soc. Trans. 46 (5), 1213–1224. doi:10.1042/BST20180519

Bartsch, H., Nair, U., Rüsch, A., Rojas, M., Wilkam, H., Alexandrov, K., et al. (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 9 (1), 3–28.

Bendaly, J., Zhao, S., Neale, J. R., Metry, K. J., Doll, M. A., States, J. C., et al. (2007). 2-Amino-3, 8-dimethylimidazo-[4, 5-f]quinoxaline-induced DNA adduct formation and mutagenesis in DNA repair-deficient Chinese hamster ovary cells expressing human cytochrome P4501A1 and rapid or slow acetylator N-acetyltransferase 2. Cancer Epidemiol. Biomarkers Prev. 16, 1503–1509. doi:10.1158/1055-9965.EPI-07-0305

Bouchardy, C., Mitrunen, K., Wikman, H., Husgafvel-Pursiainen, K., Dayer, P., Benhamou, S., et al. (1998). N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 8, 291–298. doi:10.1097/00008571-199808000-00002

Bradshaw, P. C. (2021). Acetyl-CoA Metabolism and Histone Acetylation in the Regulation of Aging and Lifespan, Antioxidants (Basel). 10, 1–43. doi:10.3390/antioxid10040572

Butcher, N. J., Arulpragassam, A., and Minchin, R. F. (2004). Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: A mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. 279, 22131–22137. doi:10.1074/jbc.M312858200

Butcher, N. J., Boukovsvala, S., Sim, E., and Minchin, R. F. (2002). Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2, 30–42. doi:10.1038/sj.tpj.6500055

Cai, L., and Tu, B. P. (2011). On acetyl-CoA as a gauge of cellular metabolic state. Cold Spring Harb. Symp. Quant. Biol. 76, 195–202. doi:10.1101/sq.2011.76.010769

Carreon, T., Rader, A. M., Schultz, P. A., Hayes, R. B., Rothman, N., Waters, M., et al. (2006). NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int. J. Cancer 118, 161–168. doi:10.1002/ijc.21308

Carrer, A., Parris, J. D. L., Trefely, S., Henry, R. A., Montgomery, D. C., Torres, A., et al. (2017). Impact of a high-fat diet on tissue acetyl-CoA and histone acetylation levels. J. Biol. Chem. 292, 3312–3322. doi:10.1074/jbc.M116.750620

Chung, K. (2013). The etiology of bladder cancer and its prevention. J. Cancer Sci. Ther. 5, 346–361. doi:10.4172/1948-5956.1000226

Degen, G. H., Schlattmann, J. H., Mahler, S., Follmann, W., and Golka, K. (2004). Comparative metabolic activation of benzo[a]pyrene and N-acetylbenzidine by prostat gland H synthase. Toxicol. Lett. 151, 135–142. doi:10.1016/j.toxlet.2003.11.015

Doll, M. A., and Hein, D. W. (2002). Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Anal. Biochem. 301, 328–332. doi:10.1006/abio.2001.5520

Doll, M. A., Zang, Y., Moeller, T., and Hein, D. W. (2010). Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. J. Pharmacol. Exp. Ther. 334, 540–544. doi:10.1124/jpet.110.186507

El Kawak, M., Dhauni, H. R., Labbou, M. E., Mousa, M. A., El Assmar, K., and Anon, M. (2020). Slow N-acetylation as a possible contributor to bladder carcinogenesis. Mol. Carcinog. 59, 1017–1027. doi:10.1002/mc.23232

Gan, J., Skipper, P. L., Gago-Dominguez, M., Arakawa, K., Ross, R. K., Yu, M. C., et al. (2004). Aldehyde-hemoglobin adducts and risk of non-smoking-related bladder cancer. J. Natl. Cancer Inst. 96, 1423–1431. doi:10.1093/jnci/djh274

Habil, M. R., Salazar-Gonzalez, R. A., Doll, M. A., and Hein, D. W. (2022). Differences in beta-naphthylamine metabolism and toxicity in Chinese hamster ovary cell lines transfected with human CYP1A2 and NAT2*4, NAT2*5B and NAT2*7B N-acetyltransferase 2 haplotypes. Arch. Toxicol. 96, 2999–3012. doi:10.1007/s00204-022-03367-2

Hest, D. W., Fakis, G., and Boukovsvala, S. (2018). Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: A mini review. Pharmagenet. Genomics 28, 238–244. doi:10.1007/978-3-319-00000-3030

Hein, D. W. (2006). N-Acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649–1658. doi:10.1038/sj.onc.1209374

Hein, D. W. (2009). N-Acetyltransferase SNPs: Emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin. Drug Metab. Toxicol. 5, 355–366. doi:10.1517/17425250902877698

Leggett, C. S., Doll, M. A., Salazar-Gonzalez, R. A., Habil, M. R., Trent, J. O., and Hein, D. W. (2012). Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1. Arch. Toxicol. 96, 511–524. doi:10.1007/s00204-012-03194-x

Acknowledgments

We thank Raul A. Salazar-González for assistance in validation of the CHO cell lines.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Leggett, C. S., Doll, M. A., States, J. C., and Hein, D. W. (2021). Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes. Arch. Toxicol. 95, 311–319. doi:10.1007/s00204-020-02901-4

Letasiova, S., Medve’Ova, A., Sevcikova, A., Dusinska, M., Volkovova, K., Mosou, C., et al. (2012). Bladder cancer, a review of the environmental risk factors. Environ. Health 11 (Suppl 1), S11. doi:10.1186/1476-069X-11-S1-S11

Millner, L. M., Doll, M. A., Cai, J., States, J. C., and Hein, D. W. (2012a). NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl. Mol. Carcinog. 51, 636–646. doi:10.1002/mc.20836

Millner, L. M., Doll, M. A., Cai, J., States, J. C., and Hein, D. W. (2012b). Phenotype of the most common “slow acetylator” arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent. Drug Metab. Dispos. 40, 198–204. doi:10.1124/dmd.111.041855

Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F., and Kroemer, G. (2015). Acetyl coenzyme A: A central metabolite and second messenger. Cell Metab. 21, 805–821. doi:10.1016/j.cmet.2015.05.014

Sim, E., Lack, N., Wang, C. J., Long, H., Westwood, I., Fullam, E., et al. (2008). Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms. Toxicology 254, 170–183. doi:10.1016/j.tox.2008.08.022

Sim, E., Pinter, K., Mushkaq, A., Upton, A., Sandy, J., Bhakta, S., et al. (2003). Arylamine N-acetyltransferases: A pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 31, 615–619. doi:10.1042/bst0310615

Xiong, Y., and Guan, K. L. (2012). Mechanistic insights into the regulation of metabolic enzymes by acetylation. J. Cell Biol. 198, 155–164. doi:10.1083/jcb.201202056

Zhou, X., Ma, Z., Dong, D., and Wu, B. (2013). Arylamine N-acetyltransferases: A structural perspective. Br. J. Pharmacol. 169, 748–760. doi:10.1111/bph.12182

Zhu, Y., and Hein, D. W. (2008). Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J. 8, 339–348. doi:10.1038/sj.tpj.6500483